ResMed (RMD) Tops Q4 EPS by 2c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BofA/Merrill Lynch Downgrades ResMed (RMD) to Neutral
August 2, 2017 6:35 AM EDTBofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral.
Analyst William Dunlop says FY 2018 should be "great" but does not believes the current trajectory is setting to make it so. The analyst comments that market share gains appear... More
